Loading…
TARO-ATENOLOL is a brand name for Atenolol, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
For management of a suspected drug overdose, contact your regional Poison Control Centre.
Hypertension:
Atenolol is usually used in conjunction with other antihypertensive agents, particularly a thiazide diuretic, but may be used alone (see INDICATIONS). The dose of atenolol should be administered in accordance with individual patient's needs.
The following guidelines are recommended:
The initial dose of atenolol is 50 mg (as 1 tablet) a day either added to diuretic therapy or alone. The full effect of this dose will usually be seen within 1 to 2 weeks. If an adequate response is not achieved, the dose should be increased to 100 mg once daily.
Increasing the dose beyond 100 mg a day is unlikely to produce any further benefit. If further lowering of the blood pressure is required, another antihypertensive agent should be added to the regimen.
Angina Pectoris:
The initial dose of atenolol is 50 mg given as one tablet a day. The full effect of this dose will usually be seen within 1 or 2 weeks. If an optimal response is not achieved within 1 week, the dosage should be increased to 100 mg given as 1 tablet a day or 50 mg twice daily.
Some patients may require a dosage of 200 mg daily for optimal effect.
Patients with Renal Impairment:
Since atenolol is eliminated predominantly via the kidneys, dosage should be adjusted in patients with severe renal impairment. 73 m2). 73m2) Atenolol Elimination Half- Life(hr) Maximum Dosage 15-35 16-27 50 mg daily <15 >27 25 mg daily Some renally-impaired or elderly patients being treated for hypertension may require a lower starting dose of TARO-ATENOLOL: 25 mg given as one tablet as day.
If this 25 mg dose is used, assessment of efficacy must be made carefully. This should include measurement of blood pressure just prior to the next dose (“trough” blood pressure) to ensure that the treatment effect is present for a full 24 hours.
14 Patients on hemodialysis should be given 25 mg or 50 mg after each dialysis; this should be done under hospital supervision as marked falls in blood pressure can occur. Dosage requirements may be reduced in the elderly, especially in patients with impaired renal function.
34 Description Atenolol is a white or almost white crystalline powder. 23. Atenolol is freely soluble in 1N HCl(300mg/mL at 25°C). 0°C.
Composition:
In addition to the active ingredient atenolol, each tablet contains the following inactive ingredients: maize starch, heavy magnesium carbonate, sodium lauryl sulphate, sodium starch glycolate, magnesium stearate, hydroxypropyl methylcellulose, colloidal silicon dioxide, polyethylene glycol 6000, purified talc and titanium dioxide.
The most serious adverse reactions encountered are congestive heart failure, AV block and bronchospasm. Bronchospasm may occur in patients with bronchial asthma or a history of asthmatic complaints. The most common adverse reactions reported in clinical trials with oral atenolol in 2 500 patients are bradycardia (3%), dizziness (3%), vertigo (2%), fatigue (3%), diarrhea (2%) and nausea (3%).
Adverse reactions occurring with an incidence of less than 1%, grouped by system, are as follows: Cardiovascular: Heart failure deterioration (see WARNINGS) Heart block Palpitations Lengthening of PR interval Chest pain, Lightheadedness Postural hypotension which may be associated with syncope Raynaud's phenomenon Intermittent claudication, or worsening of pre-existing intermittent claudication Leg pain and cold extremities Edema Respiratory: Dyspnea, wheeziness Cough Bronchospasm Central Nervous System: Faintness Ataxia Tiredness Lethargy Nervousness Depression Drowsiness Vivid dreams Insomnia Paresthesia Headache Tinnitus Mood changes Visual disturbances Psychoses and hallucinations 11 Gastrointestinal: Constipation Anorexia Abdominal discomfort, indigestion Miscellaneous: Skin rash Itchy and/or dry eyes Psoriasiform skin reactions Exacerbation of psoriasis Decreased exercise tolerance Alopecia Epistaxis Flushes Impotence, decreased libido, Sweating General body aches Thrombocytopenia and purpura.
Post-Marketing Experience During the post-marketing experience with atenolol, cold extremities, gastrointestinal disturbances and fatigue were commonly reported. The following have been reported in temporal relationship to the use of the drug: elevated liver enzymes and/or bilirubin, headache, confusion, nightmares, impotence, Peyronie's disease, psoriasisform rash or exacerbation of psoriasis, purpura, reversible alopecia and thrombocytopenia.
Rare cases of hepatic toxicity including intrahepatic cholestasis have been reported. Atenolol, like other ß-blockers, has been associated with the development of antinuclear antibodies (ANA) and lupus syndrome. 2%).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Atenolol in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Storage Recommendations TARO-ATENOLOL tablets should be stored between 15° and 30°C, protected from light and moisture. AVAILABILITY OF DOSAGE FORMS Atenolol Tablets, 25 mg are white to off white, round biconvex, film coated tablets with "25" embossing on one side and plain on other side.
Atenolol Tablets, 50 mg are white to off white, round biconvex, film coated tablets with "50" embossing on one side and score line on other side. 0 mg are white to off white, round biconvex, film coated tablets with "100" embossing on one side and score line on other side.
5 times the maximum recommended human dose) and an increased incidence of atrial degeneration of hearts of male rats at 300 but not 150 mg atenolol/kg/day (150 and 75 times the maximum recommended human dose, respectively).
Effect on cardiovascular system:
In anesthetized cats, atenolol infusion reduces the chronotropic response to isoproterenol and right cardiac sympathetic nerve stimulation. 03 mg/kg intravenous depresses the heart rate by 22%, cardiac contractile force by 16% and diastolic blood pressure by 11%.
Studies in rats showed that atenolol was devoid of intrinsic sympathomimetic activity. Atenolol in concentrations up to 10 mg/mL had no local anesthetic effect on the isolated sciatic nerve of the frog. Atenolol (5-20 mg/kg intravenous) was without effect on the ventricular tachycardia produced by toxic levels of ouabain in anesthetized dogs.
2 mg/kg intravenous) protected coronary ligated dogs from the arrhythmogenic activity of adrenaline on the fourth day after ligation (when the cardiac rhythm was predominantly sinus). Single oral doses of 100 mg atenolol given to volunteers reduced exercise-induced tachycardia by 31% at 4 hours and by 15% at 24 hours after administration.
The maximal suppression of the systolic blood pressure response to exercise was 21% at 4 hours.
Effect on plasma renin activity:
Studies in hypertensive patients have shown that the antihypertensive effect of atenolol is associated with a decrease in plasma renin activity.
Effect on pulmonary function:
The effects of a single 100 mg dose of atenolol on forced expiratory volume (FEV 1) and airways resistance (AWR) were assessed in ten patients with […]
Potential Adverse Reactions :
The following adverse reactions have occurred with other ß - blockers but have not been reported with atenolol: Cardiovascular: Pulmonary edema, cardiac enlargement, hot flushes and sinus arrest.
Central nervous syste m:
Aggressiveness, anxiety, short-term memory loss, and emotional lability with slightly clouded sensorium.
Allergic:
Laryngospasm, status asthmaticus and fever combined with aching and sore throat.
Dermatological:
Exfoliative dermatitis.
Ophthalmological:
Blurred vision, burning and grittiness.
Hematological:
Agranulocytosis.
Gastrointestinal:
Mesenteric arterial thrombosis and ischemic colitis. 12 SYMPTOMS AND TREATMENT OF OVERDOSAGE Limited information is available with regard to overdosage with atenolol in humans. Overdosage with atenolol has been reported with patients surviving acute doses as high as 5 g.
One death was reported in a man who may have taken as much as 10 g acutely. The predominant symptoms reported following atenolol overdosage are lethargy, disorder of respiratory drive, wheezing, sinus pause and bradycardia. Additionally, common effects associated with overdosage of any ß-adrenergic blocking agent are congestive heart failure, hypotension, bronchospasm and /or hypoglycemia.
Treatment should be symptomatic and supportive and directed to the removal of any unabsorbed atenolol by induced emesis, or administration of activated charcoal. Atenolol can be removed from the general circulation by hemodialysis. Further consideration should be given to dehydration, electrolyte imbalance and hypotension by established procedures.
Other treatment modalities should be employed at the physician's discretion and may include: Bradycardia: Atropine 1 to 2 mg intravenously. If there is no response to vagal blockade, give isoproterenol cautiously. In refractory cases, a transvenous cardiac pacemaker may be indicated.
Glucagon in a 10 mg intravenous bolus has been reported to be useful. If required, this may be repeated or followed by an intravenous infusion of glucagon 1 to 10 mg/hour depending on response. 5 to 10 μg/kg/minute by intravenous infusion or isoproterenol 10 to 25 μg given as an infusion at a rate not exceeding 5 μg/minute may be given, although larger doses may be required.
Heart block (second or third degree):
Isoproterenol or transvenous pacemaker.
Congestive Heart Failure:
Digitalize the patient and administer a diuretic. Glucagon has been reported to be useful.
Hypote nsion:
Vasopressors such as dopamine or norepinephrine. Monitor blood pressure continuously.
Bronchospasm:
A ß2-stimulant such as isoproterenol or terbutaline and/or intravenous aminophylline.
Hypoglycemia:
Intravenous glucose. Based on the severity of symptoms, management may require intensive support care and facilities for applying cardiac and respiratory support. 13 DOSAGE AND ADMINISTRATION For management of a suspected drug overdose, contact your regional Poison Control Centre.
Hypertension:
Atenolol is usually used in conjunction with other antihypertensive agents, particularly a thiazide diuretic, but may be used alone (see INDICATIONS). The dose of atenolol should be administered in accordance with individual patient's needs.
The following guidelines are recommended:
The initial dose of atenolol is 50 mg (as 1 tablet) a day either added to diuretic therapy or alone. The full effect of this dose will usually be seen within 1 to 2 weeks. If an adequate response is not achieved, the dose should be increased to 100 mg once daily.
Increasing the dose beyond 100 mg a day is unlikely to produce any further benefit. If further lowering of the […]